RhumbLine Advisers’s Kiniksa Pharmaceuticals KNSA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.74M | Buy |
58,529
+51,243
| +703% | +$2.66M | ﹤0.01% | 1609 |
|
|
2026
Q1 | $351K | Hold |
7,286
| – | – | ﹤0.01% | 2822 |
|
|
2025
Q4 | $301K | Hold |
7,286
| – | – | ﹤0.01% | 2965 |
|
|
2025
Q3 | $283K | Hold |
7,286
| – | – | ﹤0.01% | 3034 |
|
|
2025
Q2 | $202K | Sell |
7,286
-55,414
| -88% | -$1.41M | ﹤0.01% | 3224 |
|
|
2025
Q1 | $1.39M | Buy |
62,700
+3,745
| +6% | +$77.1K | ﹤0.01% | 2011 |
|
|
2024
Q4 | $1.17M | Sell |
58,955
-909
| -2% | -$20.7K | ﹤0.01% | 2171 |
|
|
2024
Q3 | $1.5M | Buy |
59,864
+3,798
| +7% | +$92.5K | ﹤0.01% | 2052 |
|
|
2024
Q2 | $1.05M | Sell |
56,066
-5,365
| -9% | -$101K | ﹤0.01% | 2217 |
|
|
2024
Q1 | $1.21M | Buy |
61,431
+494
| +0.8% | +$9.65K | ﹤0.01% | 2145 |
|
|
2023
Q4 | $1.07M | Sell |
60,937
-2,196
| -3% | -$36.1K | ﹤0.01% | 2212 |
|
|
2023
Q3 | $1.1M | Buy |
63,133
+3,871
| +7% | +$65.2K | ﹤0.01% | 2151 |
|
|
2023
Q2 | $834K | Buy |
59,262
+13,171
| +29% | +$176K | ﹤0.01% | 2400 |
|
|
2023
Q1 | $496K | Buy |
46,091
+1,681
| +4% | +$22.1K | ﹤0.01% | 2434 |
|
|
2022
Q4 | $665K | Buy |
44,410
+1,427
| +3% | +$20.8K | ﹤0.01% | 2335 |
|
|
2022
Q3 | $552K | Buy |
42,983
+2,939
| +7% | +$33.5K | ﹤0.01% | 2449 |
|
|
2022
Q2 | $388K | Buy |
40,044
+4,650
| +13% | +$43.4K | ﹤0.01% | 2623 |
|
|
2022
Q1 | $352K | Buy |
35,394
+737
| +2% | +$7.81K | ﹤0.01% | 2583 |
|
|
2021
Q4 | $408K | Sell |
34,657
-812
| -2% | -$9.98K | ﹤0.01% | 2593 |
|
|
2021
Q3 | $404K | Sell |
35,469
-968
| -3% | -$12.6K | ﹤0.01% | 2638 |
|
|
2021
Q2 | $508K | Buy |
36,437
+7,675
| +27% | +$117K | ﹤0.01% | 2560 |
|
|
2021
Q1 | $532K | Sell |
28,762
-1,655
| -5% | -$33.9K | ﹤0.01% | 2469 |
|
|
2020
Q4 | $537K | Buy |
30,417
+4,711
| +18% | +$82.8K | ﹤0.01% | 2415 |
|
|
2020
Q3 | $394K | Buy |
25,706
+2,424
| +10% | +$45.5K | ﹤0.01% | 2397 |
|
|
2020
Q2 | $593K | Buy |
23,282
+6,375
| +38% | +$133K | ﹤0.01% | 2271 |
|
|
2020
Q1 | $262K | Buy |
16,907
+44
| +0.3% | +$688 | ﹤0.01% | 2465 |
|
|
2019
Q4 | $187K | Buy |
16,863
+335
| +2% | +$2.91K | ﹤0.01% | 2767 |
|
|
2019
Q3 | $141K | Sell |
16,528
-38
| -0.2% | -$420 | ﹤0.01% | 2826 |
|
|
2019
Q2 | $224K | Buy |
16,566
+3,755
| +29% | +$58.3K | ﹤0.01% | 2743 |
|
|
2019
Q1 | $231K | Buy |
12,811
+4,862
| +61% | +$93.9K | ﹤0.01% | 2682 |
|
|
2018
Q4 | $223K | Buy |
+7,949
| New | +$166K | ﹤0.01% | 2681 |
|
Other funds holding KNSA
RCMNY
BBA
TCM
SSC
RhumbLine Advisers's KNSA Position: Q2 2026 in Review
RhumbLine Advisers increased its Kiniksa Pharmaceuticals (KNSA) stake by 703% in Q2 2026, buying an estimated $2.66M and bringing the position to 58,529 shares worth $3.74M. The position accounts for ﹤0.01% of the portfolio, ranked #1609.
RhumbLine Advisers first reported a position in KNSA in Q4 2018 and has held it in 31 quarters since. 266 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.
- RhumbLine Advisers held 58,529 shares of Kiniksa Pharmaceuticals worth $3.74M as of Q2 2026.
- RhumbLine Advisers bought 51,243 Kiniksa Pharmaceuticals shares in Q2 2026, an estimated $2.66M.
- Kiniksa Pharmaceuticals made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1609 holding.
- RhumbLine Advisers first reported a position in Kiniksa Pharmaceuticals in Q4 2018 and has held it in 31 quarters since.
- 266 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.